Loading...
XSHG600796
Market cap640mUSD
Jan 10, Last price  
5.42CNY
1D
-3.56%
1Q
18.86%
Jan 2017
-56.40%
Name

Zhejiang Qianjiang Biochemical Co Ltd

Chart & Performance

D1W1MN
XSHG:600796 chart
P/E
22.29
P/S
2.31
EPS
0.24
Div Yield, %
1.88%
Shrs. gr., 5y
24.15%
Rev. gr., 5y
35.66%
Revenues
2.03b
+1.27%
284,475,949285,569,137429,189,788416,659,491378,366,167357,155,423431,994,267558,968,655445,941,810482,120,871398,086,530474,020,050444,081,082467,584,528442,733,052380,287,652429,593,8772,030,900,9822,008,864,5422,034,337,262
Net income
211m
+2.25%
30,298,44328,467,66030,484,65232,452,504026,318,05049,678,93510,036,87217,625,94930,644,44322,390,10126,543,62332,832,07041,011,138026,573,6378,103,591147,938,274206,045,309210,686,886
CFO
352m
-12.42%
50,264,525094,428,2804,350,55222,743,10926,870,8950150,272,650160,022,80374,767,15262,087,01248,957,31729,755,17059,773,38455,556,57531,935,01080,633,021368,653,556401,938,595352,025,638
Dividend
Jun 27, 20240.031 CNY/sh
Earnings
May 09, 2025

Profile

Zhejiang Qianjiang Biochemical Co., Ltd. manufactures and sells biological pesticides and veterinary drugs, and pharmaceutical intermediates in China. The company provides biopesticide products comprising validamycin, gibberellic acid, abamectin, methylamino abamectin, and other products; biological drugs, including colistin sulfate premix and colistin sulphate; biological drugs intermediates; and feed additives. It also offers external heating services. In addition, the company exports its products to the United States, West Europe, South America, and Southeast Asia. Zhejiang Qianjiang Biochemical Co., Ltd. was founded in 1970 and is based in Haining, China.
URL
http://www.600796.com/
IPO date
Apr 08, 1997
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,034,337
1.27%
2,008,865
-1.09%
Cost of revenue
1,750,450
1,646,582
Unusual Expense (Income)
NOPBT
283,887
362,283
NOPBT Margin
13.95%
18.03%
Operating Taxes
45,940
50,172
Tax Rate
16.18%
13.85%
NOPAT
237,947
312,110
Net income
210,687
2.25%
206,045
39.28%
Dividends
(88,392)
Dividend yield
1.72%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
992,139
540,224
Long-term debt
974,660
1,363,602
Deferred revenue
120,981
121,410
Other long-term liabilities
331,624
327,368
Net debt
566,262
459,518
Cash flow
Cash from operating activities
352,026
401,939
CAPEX
(234,299)
Cash from investing activities
(227,207)
Cash from financing activities
(209,518)
FCF
10,694
38,425
Balance
Cash
876,278
873,207
Long term investments
524,259
571,102
Excess cash
1,298,820
1,343,865
Stockholders' equity
2,042,803
1,948,152
Invested Capital
4,617,232
4,361,643
ROIC
5.30%
7.46%
ROCE
4.80%
6.35%
EV
Common stock shares outstanding
877,862
866,586
Price
5.85
9.76%
5.33
-5.83%
Market cap
5,135,493
11.18%
4,618,902
-5.83%
EV
6,060,357
5,465,906
EBITDA
509,195
598,167
EV/EBITDA
11.90
9.14
Interest
89,119
92,433
Interest/NOPBT
31.39%
25.51%